Pureos Bioventures

Europe, Zurich, Switzerland, Küsnacht

Description

Pureos Bioventures is a new venture capital fund

Investor Profile

Pureos Bioventures has made 32 investments, with 7 in the past 12 months and 38% as lead.

Stage Focus

Series A (31%)
Series B (22%)
Series C (19%)
Seed (16%)
Series Unknown (6%)
Series F (3%)
Series D (3%)

Country Focus

Switzerland (28%)
France (25%)
The Netherlands (19%)
United States (9%)
Denmark (6%)
Germany (6%)
Singapore (3%)
Sweden (3%)

Industry Focus

Biotechnology
Health Care
Therapeutics
Medical
Life Science
Biopharma
Pharmaceutical
Medical Device
Oncology
Wellness

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Pureos Bioventures frequently co-invest with?

Kinled Holding

North America, New York, United States, New York

Co-Investments: 9

Droia Ventures

Europe, Luxembourg, Luxembourg, Luxembourg

Co-Investments: 4

RA Capital Management

North America, Massachusetts, United States, Boston

Co-Investments: 4

Novo Holdings

Europe, Hovedstaden, Denmark, Hellerup

Co-Investments: 7

Kurma Partners

Europe, Ile-de-France, France, Paris

Co-Investments: 6

Jeito Capital

Europe, Ile-de-France, France, Paris

Co-Investments: 4

Polaris Partners

North America, Massachusetts, United States, Boston

Co-Investments: 4

EQT Life Sciences

Europe, Noord-Holland, The Netherlands, Amsterdam

Co-Investments: 7

Adjuvant Capital

North America, New York, United States, New York

Co-Investments: 3

Bpifrance

Europe, Ile-de-France, France, Maisons-alfort

Co-Investments: 7

Which angels does Pureos Bioventures often collaborate with?

Fredrik Ljungström

Shared Deals: 1

AnnHelene Ljungström

Shared Deals: 1

What are some of recent deals done by Pureos Bioventures?

Callio Therapeutics

Seattle, Washington, United States

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

BiotechnologyHealth CareMedical

Series AMar 3, 2025

Amount Raised: $187,000,000

PulseSight Therapeutics

Paris, Ile-de-France, France

PulseSight Therapeutics creates innovative non-viral gene therapies using minimally invasive delivery technology.

BiotechnologyMedicalTherapeutics

Series AFeb 13, 2025

AnaCardio

Solna, Stockholms Lan, Sweden

AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.

BiopharmaBiotechnologyMedical

Series AJan 9, 2025

Amount Raised: $18,379,535

Citryll

Oss, Noord-Brabant, The Netherlands

Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.

BiopharmaBiotechnologyMedicalMedical DeviceNeuroscience

Series BDec 9, 2024

Amount Raised: $89,720,936

Alentis Therapeutics

Allschwil, Basel-Landschaft, Switzerland

ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.

BiotechnologyManufacturingPharmaceuticalTherapeutics

Series DNov 12, 2024

Amount Raised: $181,400,000

Vico Therapeutics

Leiden, Zuid-Holland, The Netherlands

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health CareMedicalPharmaceutical

Series BJun 24, 2024

Amount Raised: $12,298,137

Adcytherix

Marseille, Provence-Alpes-Cote d'Azur, France

Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).

BiotechnologyOncology

SeedJun 11, 2024

Amount Raised: $32,308,438

PulseSight Therapeutics

Paris, Ile-de-France, France

PulseSight Therapeutics creates innovative non-viral gene therapies using minimally invasive delivery technology.

BiotechnologyMedicalTherapeutics

SeedFeb 28, 2024

Vico Therapeutics

Leiden, Zuid-Holland, The Netherlands

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Health CareMedicalPharmaceutical

Series BJan 5, 2024

Amount Raised: $72,081,941

Memo Therapeutics

Schlieren, Zurich, Switzerland

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.

BiotechnologyCollaboration

Series CNov 2, 2023

Amount Raised: $27,587,120

Pureos Bioventures

Description

Investor Profile

Stage Focus

Country Focus

Industry Focus

Frequently Asked Questions

Who does Pureos Bioventures frequently co-invest with?

Which angels does Pureos Bioventures often collaborate with?

What are some of recent deals done by Pureos Bioventures?

Ready to Raise Capital?

Pages

Free tools